AI and RNA-seq for personalized leukemia care | Festina Lente - Your leading source of AI news | Turtles AI

Biostate AI and Weill Cornell Medicine have entered into a collaboration to develop RNA-seq-based AI models for AML subtype stratification, prognosis, and personalized therapy selection.

Key Points:

• BIRT Technology: Utilizes proprietary Barcode-Integrated Reverse Transcription (BIRT) technology for large-scale gene expression analysis.
• Advanced AI Models: Develops transformer-based AI models to interpret transcriptomic data.
• Strategic Collaboration: Biostate AI and Weill Cornell Medicine partner to advance clinical AI in leukemia.
• Future Expansion: Potential to expand the approach to other diseases, such as multiple sclerosis, through similar collaborations.

Biostate AI, a startup founded in 2023 by David Zhang and Ashwin Gopinath, has announced a collaboration with Weill Cornell Medicine to develop AI models aimed at personalizing the treatment of acute myeloid leukemia (AML). The agreement includes the use of the proprietary BIRT technology for RNA sequencing, allowing the detailed analysis of gene expression starting from bone marrow and blood samples. This data will feed AI models based on transformer architectures, capable of interpreting gene expression as a language, with the aim of stratifying AML subtypes, predicting prognosis and supporting therapeutic selection.

The initial phase of the project will involve the analysis of 1,000 retrospective samples, with the intent of expanding the study up to 50,000 samples, including longitudinal data of individual patients. The collaboration will benefit from the expertise of Dr. Gail J. Roboz of Weill Cornell Medicine. Biostate AI, with offices in Houston, Palo Alto, Bangalore and Shanghai, has already collaborated with over 100 research groups in the United States and has developed more than 12 patented technologies in the field of RNAseq and artificial intelligence. The company is backed by prominent investors, including Accel and Dario Amodei of Anthropic.

This initiative represents a significant step towards the integration of AI in precision medicine, with the aim of improving the diagnosis and personalized treatment of acute myeloid leukemia.